| COMPOSITION: | Empagliflozin 25 mg & Sitagliptin 100 mg |
| FORMULATION: | TABLET |
| STATUS: | PRESCRIPTION ONLY DRUG |
| DESCRIPTION: | Empaford S- 25 tablets contain Empagliflozin and Sitagliptin, two antidiabetic agents that help control blood sugar levels in type 2 diabetes. Empagliflozin, an SGLT2 inhibitor, lowers blood glucose by increasing its excretion through urine, while Sitagliptin, a DPP-4 inhibitor, enhances insulin secretion and reduces glucagon levels. Together, they improve glycemic control and help reduce the risk of diabetes-related complications. |
| SIDE EFFECTS: | Common side effects: urinary tract infections, increased urination, headache, and mild gastrointestinal discomfort. |
| DOSAGE/DIRECTIONS FOR USE: | As prescribed by the Physician. |
